Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of Nivolumab for Selected Advanced Malignancies in India
NCT03444766Phase 4Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2018
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of nivolumab in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), sponsored by Bristol Myers Squibb. Started Mar 2018; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03444766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03444766.